CAU
RMD icon

Caxton Associates (UK)’s ResMed RMD Stock Holding History

Caxton Associates (UK)’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300K Buy
+1,537
New +$319K 0.01% 640
2026
Q1 		– Sell
-4,225
Closed -$1.02M – 968
2025
Q4 		$1.02M Buy
+4,225
New +$1.08M 0.02% 355

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Caxton Associates (UK)'s RMD Position: Q2 2026 in Review

Caxton Associates (UK) opened a new position in ResMed (RMD) in Q2 2026: 1,537 shares worth $300K. The stake represents 0.01% of the portfolio and ranks #640 among its holdings. This is a return to the name: Caxton Associates (UK) previously reported a position in RMD as recently as Q4 2025.

Caxton Associates (UK) first reported a position in RMD in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.02M in Q4 2025. 887 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Caxton Associates (UK) held 1,537 shares of ResMed worth $300K as of Q2 2026.
  • ResMed was a new Caxton Associates (UK) position in Q2 2026.
  • ResMed made up 0.01% of Caxton Associates (UK)'s portfolio in Q2 2026, its #640 holding.
  • Caxton Associates (UK) first reported a position in ResMed in Q4 2025 and has held it in 2 quarters since.
  • Caxton Associates (UK)'s ResMed position peaked at $1.02M in Q4 2025.
  • 887 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.